CareDx Appoints Jing Huang Chief Data and AI Officer

CareDx Appoints Jing Huang Chief Data and AI Officer

CareDx, Inc.

Media Relations
Anna Czene
818-731-2203
aczene@caredx.com

Investor Relations
Greg Chodaczek
investor@CareDx.com

CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company’s long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024.

Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven track record in developing new products and solutions to advance patient care in the biopharma and diagnostics markets. As Chief Data and AI Officer, Huang will be responsible for advancing CareDx’s efforts to integrate data science methods and AI into its customer facing products to enhance patient care, and its internal business operations to achieve improved efficiency and scalability.

“CareDx is a leader in introducing AI-enabled rejection risk prediction models, such as AlloView™ that incorporates AlloSure®, into the clinical management of kidney transplant patients,” said John W. Hanna, CareDx President and CEO. “Our portfolio of solutions for transplant center management and patient clinical diagnosis generate a tremendous amount of utilization and genomic data that can be leveraged to build care models that further improve patient outcomes.”

Huang added, “CareDx has been at the center of many innovations which have revolutionized the field of transplantation, and today sits on one of the industry’s largest pre- and post-transplant genomics and patient outcomes databases. I'm excited to leverage this dataset along with the rich public data on transplant utilization and outcomes to drive the next wave of innovation in transplant precision medicine.”

Most recently, Huang served as Senior Vice President of Bioinformatics and Data Science at Veracyte, Inc. Huang currently also serves as the President of the Bay Area Biotech-Pharma Statistical Workshop, is the Founding President of DahShu, and is the Chapter Representative for the San Francisco Bay Area Chapter of the American Statistical Association. Huang completed her Doctorate in Statistics from Stanford University. In 2023, Huang was elected as lifetime Fellow of the American Statistical Association to recognize her outstanding contributions to the medical research community in the field of statistics for numerous statistical innovations in genomic tests, and for exemplary leadership and community service to the profession.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.